

C l a i m s:

1. Active agent combination for the diagnostics and treatment of tumors, comprising a water-soluble complex or a water-soluble compound of pure hypericin, as the case may be, and a poly-N-vinylamide.
2. Active agent combination according to claim 1, characterized in that it comprises a water-soluble complex or a water-soluble compound of pure hypericin, as the case may be, and polyvinylpyrrolidone (PVP) of different degrees of polymerization and cross-linking.
3. Active agent combination according to claim 2, characterized in that the polyvinylpyrrolidone exhibits a degree of polymerization of low molar weights, preferably of 10000-90000 g/mol, particularly preferred of 10000-40000 g/mol.
4. Active agent combination according to any one of claims 1 to 3, characterized in that in the active agent combination the molar ratio of hypericin to poly-N-vinylamide is about 1:1.
5. Active agent combination according to any one of claims 1 to 4, characterized in that the concentration of hypericin and of poly-N-vinylamide (e.g. PVP) is from 1 μ mol/l to 0,1 mol/l each.
6. Process for the production of an active agent combination according to any one of claims 1 to 5, characterized in that hypericin is bonded or complexed, as the case may be, with a poly-N-vinylamide, preferably PVP.
7. Process according to claim 6, characterized in that the complexing is carried out in aqueous, optionally buffered solution.
8. Process according to any one of claims 6 or 7, characterized in that the active agent combination further is provided in a way known per se for the intravenous, intracavitary, inhalative, oral, intraperitoneal and topical administration, in hydrophilic or hydrophobic carriers, preferably in form of a solution, a cream, a gel, an aerosol, of emulsions or as a plaster.
9. Use of the active agent combination according to any one of claims 1 to 5 for the production of a medicament.
10. Use according to claim 9 for the production of a medicament for the treatment of tumors and diseased tissue.
11. Use of the active agent combination according to any one of

claims 1 to 5 for the production of a means of diagnosis for photophysical or photodynamic diagnostics, as the case may be, and for the early cancer diagnosis.